All News

2070 articles, sorted by publication time.

biology · global

Parkinson's Disease Stem Cell Brain Transplants Pass Early Safety Threshold

An early human trial conducted in Sweden and the United Kingdom shows that implanting dopamine progenitor cells derived from embryonic stem cells into the brain produced no major safety signals directly related to the cell product during the first year of follow-up; however, this remains a small, open-label trial, and there is still some distance to go before efficacy is proven and the approach can move toward routine treatment.

Biomedicine · global

Huntington’s Disease Stem Cell Therapy Enters the Clinic for the First Time, Putting the Idea of Repairing Neural Circuits to the Test in Humans

A clinical trial of a stem cell therapy for Huntington’s disease has been announced; it moves a concept long confined to regenerative medicine and animal studies into patients, but publicly available information remains limited, and the real answers still depend on whether safety, cell survival, and functional improvement can be rigorously measured.

Biotech Industry · global

Zhangjiang Pharma Valley Back in the Spotlight: The Next Test for China’s Biotech Cluster

Shanghai Zhangjiang’s biopharmaceutical strength is moving from a story of park-level investment attraction toward a more rigorous industrial test: whether R&D, clinical development, manufacturing, and capital can connect into a reliable long chain will determine whether “Pharma Valley” can turn clustering effects into real new-drug competitiveness.

biology · global

mRNA Cancer Vaccines Do Not Rely on Just One Immune Pathway, as Dendritic Cell “Backup System” Rewrites Ideas About Antitumor Immunity

A mouse study indicates that mRNA lipid nanoparticle vaccines can still activate cancer-killing T cell responses through cDC2 cells even in the absence of cDC1 dendritic cells, long viewed as critical; this gives cancer vaccine design another tunable immune entry point, while also underscoring that clinical translation still requires validation in humans.

Biopharmaceuticals · global

Belvarafenib Phase 2 Progress Presented at Korean Cancer Association Meeting, as Hanmi Moves RAF Targeted Therapy Toward More Rigorous Clinical Testing

This is not a results announcement that is enough to rewrite treatment standards, but a key progress disclosure on the path of cancer targeted drug development: whether a candidate drug can move from mechanistic rationale to patient benefit will still depend on how the Phase 2 trial data mature.